JPRN-UMIN000011023
Completed
Phase 2
A Phase II Study of Neo-adjuvant Combination Therapy of Trastuzumab and Anastrozole for Hormone Receptor-Positive, HER2-Positive Postmenopausal Breast Cancer(WJOG7412B) - "TRAstuzumab and ANAstrozole for breast cancer" WJOG7412B/Tra-Ana study
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Hormone receptor-positive, HER2-positive postmenopausal breast cancer
- Sponsor
- West Japan Oncology Group
- Enrollment
- 70
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Active infection under treatment 2\)Concurrent serious disease or condition 3\)Pulmonary fibrosis or interstitial pneumonitis by chest X\-ray 4\)Abnormal electrocardiography findings with clinical symptoms 5\)Patients with other active malignancies 6\)Concurrent serious psychiatric disorder 7\)Concurrent massive body cavity fluid (pleural effusion, ascites or cardiac effusion, etc)needs treatment 8\)Concurrent continuous systemic treatment with steroids 9\)History of serious allergic reactions 10\)HBsAg or HCVAb\-positive 11\)Patient considered irrelevant by the attending physician for the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Phase II study of neoadjuvant combination chemotherapy with TS-1, cisplatin and Paclitaxel (PCS) for resectable advanced gastric cancer.resectable advanced gastric cancerJPRN-UMIN000006674Kinki University Faculty of Medicine20
Active, Not Recruiting
Phase 1
Phase Ib/II study assessing the neo-adjuvant combination therapy of vinflunine with cisplatin followed by radical cystectomy in patients with muscle-invasive bladder cancerEUCTR2016-000081-33-DEigartis GmbH42
Recruiting
Phase 2
Phase II trial exploring combined neoadjuvant therapy with Pembrolizumab/Lenvatinib and adjuvant Pembrolizumab in patients with surgically resectable Non-Small- Cell Lung Cancer (NSCLC)2024-514821-45-00Medizinische Universitaet Innsbruck33
Recruiting
Phase 1
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma.glioblastomaMedDRA version: 20.0Level: PTClassification code: 10018337Term: Glioblastoma multiforme Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2023-508278-26-01Z Brussel18
Active, Not Recruiting
Phase 1
Clinical trial for the evaluation of a new drug (cabozantinib) treatment given before having kidney surgery in patients with kidney cancer that is advanced or has spreadocally Advanced or Metastatic Renal Cell CarcinomaMedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001201-93-ESFundación ONCOSUR50